# Twinlab Consolidated Holdings, Inc. · Edgar & Edgarette company card

> Twinlab Consolidated Holdings saw revenue fall 14.3% in FY2024 to $12 million, operating margin -15.2% against a 0.7% median for medicinal chemicals & botanical products, equity -2466% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1590695 · fiscal year ended 2024-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/1590695) · [JSON](https://www.pops4.com/boards/company/1590695.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $12M |
| Revenue growth, 1 year | -14.3% |
| Revenue growth per year | -35.2% |
| Operating margin | -15.2% (prior year -10.2%) |
| Net margin | -81.4% |
| Operating cash flow | −$273,000 |
| Capital spending | $2,000 |
| Free cash flow | −$275,000 |
| Cash | $13,000 |
| Long-term debt | $94M |
| Total assets | $6M |
| Total equity | −$149M |
| Equity ÷ assets | -2465.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -371.7 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed bankruptcy or receivership, debt accelerated or triggered, material impairment in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -15.2% in FY2024; revenue is hard to predict: its 80% range is ±40%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $11.7M (FY2024), total debt $93.9M. Experience: revenue down 14.3% on the year, down 35.2% a year over 4 years; operating margin -15.2%, down from -10.2%. Soundness: equity -2465.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.2M and $12.3M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $4.9M to $13.0M. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -15.2% against a 0.7% median; growth -14.3% against 1.7%.

## Health Watch, last 12 months

- Item 1.03 Bankruptcy or receivership: 1, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392626001687/0001753926-26-001687-index.htm))
- Item 2.04 Debt accelerated or triggered: 1, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392626001687/0001753926-26-001687-index.htm))
- Item 2.06 Material impairment: 1, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392626001687/0001753926-26-001687-index.htm))

## Recent filings

- 8-K · filed 2026-09-02 · 1.01 Entry into a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 2.01 Completion of Acquisition or Disposition of Assets; 2.04 Triggering Events That Accelerate a Financial Obligation; 2.06 Material Impairments; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392626001687/0001753926-26-001687-index.htm)
- 10-K · filed 2026-03-03 · [filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392626000426/0001753926-26-000426-index.htm)
- 10-Q · filed 2025-10-16 · [filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392625001621/0001753926-25-001621-index.htm)
- 10-Q · filed 2024-08-01 · [filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392624001309/0001753926-24-001309-index.htm)
- 10-Q · filed 2024-05-09 · [filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392624000938/0001753926-24-000938-index.htm)
- 10-K · filed 2024-03-19 · [filing](https://www.sec.gov/Archives/edgar/data/1590695/000175392624000562/0001753926-24-000562-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001590695.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1590695

## Cite

POPS4, Edgar & Edgarette: Twinlab Consolidated Holdings, Inc. company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/1590695. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.